Discovery of JNJ-787: An Hpk1 inhibitor that enhances the anti-tumor immunity of anti-PD1 in mice

被引：0
|
作者：
Mevellec, Laurence [2 ]
Descamps, Sophie [2 ]
Adelinet, Christophe [2 ]
Wroblowski, Berthold [1 ]
Vreys, Veronique [1 ]
Valckx, Annemie [1 ]
Boeckx, Inge [1 ]
Van Slycken, Nele [1 ]
Paulussen, Caroline [1 ]
Leclercq, Laurent [1 ]
Verhulst, Tinne [1 ]
Van der Leede, Bas-jan [1 ]
Angibaud, Patrick [2 ]
Meerpoel, Lieven [1 ]
Edwards, James [3 ]
Laquerre, Sylvie [3 ]
Lorenzi, Matt [3 ]
Vialard, Jorge [1 ]
机构：
[1] Janssen Res & Dev, Beerse, Belgium
[2] Janssen Res & Dev, Val De Reuil, France
[3] Janssen Res & Dev, Spring House, PA USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2019年 / 257卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
5
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
    A Ray
    D S Das
    Y Song
    T Hideshima
    Y-T Tai
    D Chauhan
    K C Anderson
    Leukemia, 2018, 32 : 843 - 846
  • [42] Copanlisib enhances the effectiveness of anti-PD1 therapies for colorectal cancer
    Schmitz, Alexa E.
    Maduscha, Kennedy J.
    Makkar, Sarbjeet
    Pasch, Cheri A.
    DeStefanis, Rebecca A.
    Emmerich, Philip B.
    Deming, Dustin A.
    CANCER RESEARCH, 2023, 83 (07)
  • [43] Deletion of Pak1 enhances anti-tumor immunity by the activation of dendritic cells
    Okumura, Kazuhiro
    Morinaga, Takao
    Tanaka, Sora
    Otoyama, Keisuke
    Tokunaga, Yurika
    Saito, Megumi
    Araki, Kimi
    Wakabayashi, Yuichi
    CANCER SCIENCE, 2024, 115 : 134 - 134
  • [44] Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumor mouse models
    Rolland, S.
    Klinz, S. G.
    Meyer-Losic, F.
    Nahkle, J.
    Delille, R.
    de Boisferon, M. Hillairet
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] Anti-tumor effects of genetic deletion of PD-1 in adult mice
    Raghavan, Sukaya
    Tovbis, Nataliya Shifrin
    Kochel, Christina
    Malefyt, Rene deWaal
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2017, 86 (04) : 339 - 340
  • [46] PD-L1 blockade enhances anti-tumor efficacy of NK cells
    Oyer, Jeremiah L.
    Gitto, Sarah B.
    Altomare, Deborah A.
    Copik, Alicja J.
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [47] Unleashing anti-tumor immunity through anti-OX40 monotherapy and in combination with anti-PD-L1
    Kim, Jeong M.
    CANCER RESEARCH, 2015, 75
  • [48] Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models
    Setsu, Genzui
    Goto, Megumi
    Ito, Kentaro
    Taira, Tomoe
    Miyamoto, Masaya
    Watanabe, Tomohiro
    Taniguchi, Toru
    Umezaki, Yuma
    Nakazawa, Yusuke
    Uesugi, Shuhei
    Mori, Kazuki
    Horiuchi, Takao
    Obuchi, Wataru
    Minami, Masako
    Shimada, Takashi
    Wada, Chisa
    Yoshida, Takanori
    Higuchi, Saito
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 961
  • [49] Synergistic anti-tumor activity with a combination of anti-PD1 antibody and the cyclophilin inhibitor, rencofilstat, in the Hep53.4 fatty liver model of hepatocellular carcinoma
    Ure, Daren
    Leslie, Jack
    Variya, Bhavesh
    Foster, Robert
    Mann, Jelena
    Mann, Derek A.
    JOURNAL OF HEPATOLOGY, 2022, 77 : S660 - S660
  • [50] DIFFERENCES IN THE PATTERNS OF ANTI-PD1 (PD1) TOXICITY BETWEEN TUMOR STREAMS
    Sabanathan, D.
    Kong, B.
    Byrne, N.
    Wegener, V.
    Eslick, G.
    Nagrial, A.
    Hui, R.
    Kefford, R.
    Gurney, H.
    Carlino, M. S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 68 - 68
12345